300 Shares in Moderna, Inc. (NASDAQ:MRNA) Acquired by Westside Investment Management Inc.

Westside Investment Management Inc. acquired a new position in Moderna, Inc. (NASDAQ:MRNA) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 300 shares of the company’s stock, valued at approximately $32,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of MRNA. Ogorek Anthony Joseph NY ADV bought a new position in Moderna in the fourth quarter worth approximately $27,000. Arlington Trust Co LLC grew its stake in Moderna by 4,833.3% in the fourth quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock worth $29,000 after purchasing an additional 290 shares in the last quarter. Rise Advisors LLC grew its stake in Moderna by 953.3% in the first quarter. Rise Advisors LLC now owns 316 shares of the company’s stock worth $34,000 after purchasing an additional 286 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in Moderna by 32.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 475 shares of the company’s stock worth $47,000 after purchasing an additional 116 shares in the last quarter. Finally, CVA Family Office LLC boosted its position in Moderna by 242.3% during the 1st quarter. CVA Family Office LLC now owns 445 shares of the company’s stock valued at $47,000 after acquiring an additional 315 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Insiders Place Their Bets

In other Moderna news, CFO James M. Mock sold 705 shares of the stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $101.93, for a total transaction of $71,860.65. Following the sale, the chief financial officer now directly owns 5,048 shares of the company’s stock, valued at approximately $514,542.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CFO James M. Mock sold 705 shares of the firm’s stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $101.93, for a total transaction of $71,860.65. Following the sale, the chief financial officer now directly owns 5,048 shares in the company, valued at approximately $514,542.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO James M. Mock sold 648 shares of the firm’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $162.47, for a total value of $105,280.56. Following the sale, the chief financial officer now owns 5,726 shares in the company, valued at $930,303.22. The disclosure for this sale can be found here. In the last three months, insiders have sold 396,255 shares of company stock valued at $54,593,731. Company insiders own 15.20% of the company’s stock.

Moderna Stock Performance

Shares of MRNA stock opened at $115.95 on Friday. The firm has a market capitalization of $44.44 billion, a price-to-earnings ratio of -7.40 and a beta of 1.66. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.03 and a quick ratio of 3.91. The business has a fifty day moving average of $134.88 and a 200 day moving average of $112.67. Moderna, Inc. has a 1 year low of $62.55 and a 1 year high of $170.47.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share for the quarter, topping the consensus estimate of ($3.59) by $0.52. The company had revenue of $167.00 million for the quarter, compared to the consensus estimate of $93.26 million. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. The firm’s revenue for the quarter was down 91.0% compared to the same quarter last year. During the same period last year, the firm earned $0.19 EPS. As a group, research analysts expect that Moderna, Inc. will post -7.46 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Oppenheimer increased their target price on Moderna from $163.00 to $179.00 and gave the company an “outperform” rating in a research report on Wednesday, June 12th. Jefferies Financial Group reaffirmed a “buy” rating and set a $125.00 target price on shares of Moderna in a research report on Tuesday, April 9th. William Blair reaffirmed a “market perform” rating on shares of Moderna in a research report on Thursday, June 27th. Evercore ISI reaffirmed an “in-line” rating and set a $120.00 target price on shares of Moderna in a research report on Thursday, June 27th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a research report on Friday, June 28th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $134.02.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.